As of November 6, 2026, Agios Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: AGIO); its largest reported holder is Farallon Capital Management, L.L.C., with 9.9% on Schedule 13G/A of August 3, 2026, then Dapice Joshua J. (8.8%). The largest insider holding is Brian Goff, the chief executive and a director, with 184,508 shares (0.31% of shares outstanding), per Form 4 of April 6, 2026 (Schedule 13G/A, August 3, 2026).
Is this your company?
About to sign with, pay or invest in Agios Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Agios Pharmaceuticals, Inc. a real, registered company?
- Agios Pharmaceuticals, Inc. files with the SEC under CIK 1439222 (its SEC filings).
- Its shares are listed under the ticker AGIO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under AGIOS PHARMACEUTICALS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Farallon Capital Management, L.L.C. (filed 2026-08-03).
Who are Agios Pharmaceuticals, Inc.'s owners and officers?
Agios Pharmaceuticals, Inc.: incorporated in Delaware; business address in Cambridge, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-03).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-03 | Farallon Capital Management, L.L.C. | 9.9% |
| Schedule 13G, 2026-07-02 | D. E. Shaw & Co., L.P. | 5.1% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 4.57% |
| Schedule 13G, 2026-05-06 | Lynx1 Capital Management LP | 5.1% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.27% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G, 2026-02-17 | Armistice Capital, LLC | 5.21% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 5.3% |
| Schedule 13G/A, 2026-02-09 | Dapice Joshua J. | 8.8% |
| Schedule 13G/A, 2025-12-05 | Bellevue Group Ag | 0% |
| Schedule 13G/A, 2025-11-14 | Paradigm Biocapital Advisors LP | 4.9% |
| Schedule 13G, 2025-08-28 | Paradigm Biocapital Advisors LP | 5.2% |
Questions about who owns Agios Pharmaceuticals, Inc.
Who owns Agios Pharmaceuticals, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Agios Pharmaceuticals, Inc.: Farallon Capital Management, L.L.C. (9.9%, Schedule 13G/A, filed 2026-08-03), Dapice Joshua J. (8.8%, Schedule 13G/A, filed 2026-02-09), State Street Corporation (5.3%, Schedule 13G, filed 2026-02-09), Vanguard Capital Management (5.27%, Schedule 13G, filed 2026-04-29) and D. E. Shaw & Co., L.P. (5.1%, Schedule 13G, filed 2026-07-02); 1 more is listed above.
Who are the largest shareholders of Agios Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Agios Pharmaceuticals, Inc. on this page are Farallon Capital Management, L.L.C. (9.9%), Dapice Joshua J. (8.8%) and State Street Corporation (5.3%).
When did Farallon Capital Management, L.L.C. buy into Agios Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Farallon Capital Management, L.L.C. on this page is the Schedule 13G/A, filed 2026-08-03, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Agios Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Agios Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Agios Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Agios Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 184,508 shares (0.31% of shares outstanding) (Form 4, 2026-04-06).
- , a director: 154,156 shares (0.26% of shares outstanding) (Form 4, 2026-06-23).
- , the chief financial officer: 54,998 shares (0.09% of shares outstanding) (Form 4, 2026-04-06).
- , the chief medical officer: 54,645 shares (0.09% of shares outstanding) (Form 4, 2026-10-28).
- , the chief legal officer: 49,306 shares (0.08% of shares outstanding) (Form 4, 2026-04-06).
Shares outstanding: 59,809,651 as of 2026-10-30, from the company's latest SEC cover page.
How much has Agios Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Agios Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Agios Pharmaceuticals, Inc. and the records around it.
Agios Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/agios-pharmaceuticals